通过抑制AMPK介导的自,MLKL促进肝癌发生
Xianjun Yu1,2, Mengyuan Feng1,2, Jian Guo2
1Department of Gastroenterology, Renmin Hospital, School of Basic Medical Sciences, Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, 442000, China.
混合系激酶域样 (MLKL) 通过抑制自和AMPK活性来驱动肝癌. 抑制MLKL显示了肝细胞癌 (HCC) 的治疗潜力.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 细胞死亡研究 细胞死亡研究
背景情况:
- 混合系基因酶域样 (MLKL) 对于亡至关重要.
- MLKL在肝癌发生中的作用尚未完全理解.
- 新出现的证据将MLKL与肝病进展联系起来.
研究的目的:
- 调查MLKL在肝细胞癌 (HCC) 发展中的作用.
- 阐明MLKL影响肝癌发生的机制.
- 在肝癌的背景下探索MLKL-AMPKα1相互作用.
主要方法:
- 甲胺 (DEN) 诱导的小鼠HCC模型.
- 肝细胞特异性MLKL淘汰和过度表达研究.
- 对MLKL与AMPKα1和PPM1B相互作用的分析.
- 评估自活性激活和AMPKα1酸化.
主要成果:
- 在DEN诱导的HCC和人类HCC组织中,MLKL被上调.
- MLKL淘汰赛抑制了HCC的进展;MLKL过度表达加速了它.
- 删除MLKL激活了自和保护HCC.
- MLKL通过与PPM1B架桥直接抑制AMPKα1活动,减少AMPKα1酸化.
结论:
- MLKL充当AMPK守门员,抑制自并促进肝癌发生.
- MLKL-AMPKα1轴代表了HCC的潜在治疗目标.
- 准MLKL可能通过恢复自性来提供HCC治疗的新策略.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
cAMP-dependent Protein Kinase Pathways
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
